Thu, 11 Jun 2026 · LIVE
Updated Aug 30, 2025 · 19:14
Health News Updated Aug 30, 2025

Train ASHA workers to identify babies with Spinal Muscular Atrophy: Experts

Spinal Muscular Atrophy (SMA) is a rare genetic disorder affecting motor capabilities in children with significant diagnostic challenges. Health experts are advocating for community health workers like ASHA to be trained in early detection and milestone recognition. The lack of a national registry and standardized screening protocols currently hinders comprehensive management of the condition. Collaborative efforts between governments, medical professionals, and patient bodies are essential to improve diagnosis and treatment accessibility.

New Delhi, Aug 30

Training ASHA workers to identify red flags in babies with Spinal Muscular Atrophy can be a major boost in the fight against the rare disease in India, said health experts on Saturday.

SMA is a rare genetic disorder that affects the motor capabilities of the person affected.

In SMA, intellectual capacities remain normal, but motor capacities are affected.

Speaking to IANS, Dr. Rahul UR, State Nodal Officer - Child Health and Rare Diseases, National Health Mission, Kerala, said that understanding the disease process is crucial.

"SMA is a genetic disorder that presents in early childhood and is often mistaken for a simple developmental delay, unlike adult motor issues that might lead to needing a wheelchair," Rahul said.

SMA is categorised into four types -- numbered as type 0, 1, 2, 3, and 4.

Type 0 are those babies who don't survive the labour process due to a lack of muscle function, resulting in death. In Types 1 to 4, the recruitment of the motor units is affected, resulting in a neuromuscular disorder.

The expert cited that a key problem is that many parents are unaware of the major developmental milestones a child should achieve by a certain age.

Therefore, building awareness starts with understanding the normal stages of a child's development. This education can easily be integrated into existing national health programmes.

"Missing key milestones, such as attaining neck control or learning to stand by the appropriate age, are critical indicators that require further evaluation," Rahul said.

For example, a child with Type 1 SMA will never achieve neck control without treatment. Unfortunately, some families might believe their child will simply catch up later.

"This causes them to wait, delaying both evaluation and diagnosis. For a child with Type 1 SMA, such a delay can be fatal within the first year of life," Rahul told IANS.

To avoid this, "community health professionals, like ASHA workers, can be trained to identify red flags. This must be complemented by a push for early screening and newborn testing programmes to catch these conditions systematically," the expert said.

Importantly, the expert cited the lack of standard guidelines or protocols for the management of SMA as well as the lack of a national registry to understand the number of SMA patients. There is also a lack of sustainable funding, which can help improve diagnostics and treatments for the disease.

"As per literature, the estimated number of SMA cases in India is around 1 in 7,500. However, we do not have an exact registry or records of this condition. This issue is not limited to the case of Spinal Muscular Atrophy but most rare diseases in India," the doctor said.

"Today, the SMA ecosystem in India faces critical gaps -- delayed diagnosis and initiation of treatment due to limited awareness and inadequate access to genetic testing facilities, limited number of Centres of Excellence with trained specialists and multidisciplinary teams to provide holistic care and lack of sustainable funding to access treatment," Professor Sheffali Gulati, neurologist at the Department of Paediatrics, AIIMS, New Delhi, told IANS.

The continued delay in building robust data systems threatens public health significantly because the healthcare workers cannot plan for sustainable, population-level support without it.

Gulati noted that although innovative therapies are now available and have shown proven outcomes in preserving motor function and improving quality of life, access remains a major challenge.

"To truly change the trajectory for patients, India urgently needs a sustainable funding mechanism that ensures equitable access to these life-changing therapies," she added.

To bridge these gaps, the experts urged governments, NGOs, patient bodies, the medical fraternity, and the industry to come together with a shared commitment.

(Rachel V Thomas can be contacted at rachel.t@ians.in)

— IANS

Reader Comments

Rahul R

As a parent, I wish I knew about these developmental milestones earlier. Many of us in smaller towns just assume our children will "catch up" later. Awareness is key!

Dr. Amit K

Excellent suggestion but implementation will be challenging. We need proper training modules and follow-up systems. Also, the lack of national registry for rare diseases is a major gap in our healthcare system.

Sunita J

My cousin's child has SMA. The struggle for diagnosis and treatment was heartbreaking. Early detection through ASHA workers could prevent so much suffering. Government should prioritize this!

Michael C

While training ASHA workers is good, we also need to address the treatment accessibility issue. What's the point of early diagnosis if families can't afford the treatment? Sustainable funding mechanism is crucial.

Anjali F

This should be part of the regular ASHA training curriculum. So many rare diseases go undiagnosed in rural India. Hope the government acts quickly on this recommendation! 💪

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Reader Voices

Leave a comment

Be kind. Add to the conversation. 0/50
Thank you — your comment has been submitted.
JS blocked